mp.weixin.qq.com·· 7 days agoScore40
Verastem and GenFrog Share First Multi-Tumor Data for Oral KRAS G12D Inhibitor VS-7375 in TARGET-D 101
In brief
Verastem and GenFrog Therapeutics (Jinfang) have disclosed the first tumor-agnostic data from the phase 1/2 TARGET-D 101 trial of VS-7375, also known as GenFrog's GFH375, an oral KRAS G12D (ON/OFF) inhibitor. GenFrog retains rights in greater China while Verastem handles development and commercialization elsewhere. The data were presented on October 14.
Source: mp.weixin.qq.com · mp.weixin.qq.com